AndroGel Cost in Utah 2026: Cash Pay, Insurance, Medicaid, and Compounded Alternatives

What Does AndroGel Actually Cost in Utah Right Now?

AndroGel's AbbVie wholesale acquisition cost runs approximately $510 per month in 2026 for the 1.62% formulation. That figure rarely reflects what a Utah patient actually pays at the counter. The real number depends on insurance tier placement, coupon stacking, pharmacy choice, and whether a prescriber recommends branded or compounded product.

Utah retail pharmacy data compiled for 2026 shows cash-pay prices for a 30-day supply of AndroGel 1.62% (75 g pump) clustering around $490 to $515 at major chains such as Smith's, Walgreens, and CVS. Independent pharmacies occasionally price lower, particularly when they stock the authorized generic. GoodRx and similar discount platforms have brought some Utah cash prices down to the $380 to $430 range on branded product, though availability fluctuates by zip code.

The FDA approved testosterone gel under NDA 021449 for men with primary or secondary hypogonadism characterized by signs and symptoms consistent with low testosterone plus confirmed low morning serum testosterone on at least two separate measurements [1]. Prescribers in Utah must adhere to that labeled indication when writing a commercially covered prescription.

Generic testosterone gel 1.62% entered the U.S. market after the brand's exclusivity period and carries materially lower cash prices, often $150 to $250 per month at Utah pharmacies, making it the most affordable FDA-approved topical testosterone option short of compounding.

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled trials in men 65 years and older with low testosterone (serum testosterone <275 ng/dL), found that testosterone gel treatment for 12 months produced statistically significant improvements in sexual function and bone mineral density, providing the clinical rationale that continues to underpin prescribing patterns nationwide [2]. Those findings reinforce why clinicians and patients pursue coverage for the drug even at high list prices.

Does Utah Medicaid Cover AndroGel?

Utah Medicaid does not cover AndroGel or its generic equivalents for male hypogonadism as of 2026. This exclusion applies to both traditional Medicaid and the Utah Medicaid expansion population managed through accountable care organizations. The Utah Department of Health and Human Services pharmacy benefit list does not include testosterone replacement therapy for this indication among covered outpatient drugs [3].

Male hypogonadism coverage exclusions are common in state Medicaid programs. A 2022 analysis published in JAMA Internal Medicine found that testosterone therapy coverage in state Medicaid formularies remained inconsistent, with several states explicitly excluding topical formulations [4]. Utah falls in that non-covered category.

Patients on Utah Medicaid who receive a confirmed hypogonadism diagnosis have three practical paths. First, they may request a prior authorization appeal with documentation of medical necessity, though approval rates for AndroGel specifically are low. Second, they may pursue testosterone cypionate or testosterone enanthate injectable formulations, which some Utah Medicaid plans do cover at generic prices well below $50 per month. Third, they may use 503A compounded testosterone gel paid out of pocket, which at roughly $120 per month is far more accessible than the $510 list price for the brand.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We recommend against prescribing testosterone therapy to men with age-related decline in testosterone concentrations who do not have symptoms or signs of hypogonadism." [5] That guideline framing matters for Medicaid prior authorization submissions, because coverage is more defensible when the clinical record documents both biochemical and symptomatic criteria.

Is Compounded Testosterone Gel Legal in Utah?

Compounded testosterone gel is legal in Utah when dispensed by a 503A-licensed pharmacy operating under a valid patient-specific prescription. Several Utah pharmacies hold 503A status under FDA and Utah Division of Occupational and Professional Licensing oversight [6]. They may compound testosterone gel in concentrations and delivery vehicles not commercially available, often at substantially lower cost.

503A compounding pharmacies prepare drug products for specific patients based on a valid prescriber order. They operate differently from 503B outsourcing facilities, which produce sterile bulk products for healthcare institutions. For testosterone gel, 503A is the relevant category. The FDA limits 503A compounding from bulk drug substances to substances on its approved list or those under clinical need review [7].

Testosterone is on the FDA's list of bulk drug substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, making Utah 503A-compounded testosterone gel lawful under both federal and state rules [6, 7].

Utah patients receiving compounded testosterone gel typically pay $100 to $140 per month depending on concentration, vehicle (hydroalcoholic gel vs. cream), and dispensing pharmacy. Most compounding pharmacies in Salt Lake City, Provo, and St. George accept electronic prescriptions from telehealth providers with valid Utah or interstate prescribing authority.

The HealthRX clinical team uses a three-tier cost framework for Utah testosterone gel patients: (1) Generic FDA-approved gel for patients with commercial insurance that tiers it favorably; (2) 503A-compounded gel for cash-pay or Medicaid patients who need topical delivery; (3) Testosterone cypionate injection for patients on Utah Medicaid who need the lowest-cost covered option. This framework reduces average monthly spend by 60 to 75 percent compared with defaulting to branded AndroGel at list price.

How Insurance Coverage Works for AndroGel in Utah

Commercial insurance coverage for AndroGel in Utah varies by plan and formulary tier. Most major carriers operating in Utah, including SelectHealth, PEHP (Public Employees Health Program), Regence BlueCross BlueShield of Utah, and UnitedHealthcare, list testosterone gel products on their formularies, but tier placement differs substantially.

SelectHealth places generic testosterone gel on Tier 2 for most employer plans, yielding a copay of $30 to $60 per month after deductible [8]. Branded AndroGel typically lands on Tier 3 or Tier 4, where patient cost-sharing commonly reaches $80 to $200 per fill, sometimes with a quantity limit requiring step therapy through the generic first.

PEHP, which covers Utah state employees, requires prior authorization for branded AndroGel and mandates a trial of generic testosterone gel before approving the brand. Meeting that step-therapy requirement typically takes 90 days.

A 2023 study in the Journal of Managed Care and Specialty Pharmacy found that prior authorization requirements for testosterone replacement therapy were associated with a 34% reduction in therapy initiation and a 22% increase in time to first fill, underscoring the real-world burden these requirements place on patients [9].

The Affordable Care Act does not mandate testosterone therapy coverage, so plan-level formulary decisions govern. Patients should request a formulary exception in writing from their insurer when the preferred tier product is medically contraindicated or fails. A prescriber letter documenting confirmed hypogonadism with two low morning testosterone values and symptom burden supports the exception request.

How Does the AbbVie Savings Card Work in Utah?

AbbVie's myAbbVie Assist copay card program is available to commercially insured Utah patients who are not enrolled in any federal or state government health program, including Medicare, Medicaid, CHIP, TRICARE, or the VA. Eligible patients may pay as little as $0 per month for AndroGel with a valid prescription [10].

The card works by covering the gap between the patient's insurance copay and the AbbVie-defined out-of-pocket cap. If a Utah SelectHealth plan charges a $150 monthly copay for Tier 4 AndroGel, AbbVie's program covers that amount up to program limits, leaving the patient paying $0 or a minimal amount. Program details and annual caps are subject to change. Patients should verify current terms directly at the AbbVie patient assistance website or by calling 1-800-222-6885.

Cash-pay patients without any insurance are generally not eligible for the copay card. They may qualify instead for the myAbbVie Assist patient assistance program, which provides free medication to patients meeting income criteria typically set at or below 400% of the federal poverty level. A Utah household of two with an annual income below approximately $79 to 480 in 2025 may qualify [10].

Patients who use GoodRx or similar coupons cannot simultaneously use the AbbVie copay card on the same prescription. Pharmacists must process one discount mechanism at a time.

What Are the Cheapest Ways to Get Testosterone Gel in Utah?

Several strategies reduce cost, and the optimal one depends on insurance status.

For commercially insured Utah patients, requesting step therapy to generic testosterone gel 1.62% is typically the lowest copay path. Generic gel at a Tier 2 copay of $30 to $60 per month represents a 90 percent reduction from the $510 brand list price. Patients who medically require branded AndroGel should combine commercial insurance with the AbbVie copay card.

For uninsured or cash-pay patients, 503A-compounded testosterone gel at approximately $120 per month is the most cost-effective topical option. Patients should confirm the pharmacy's 503A licensure through the Utah Division of Occupational and Professional Licensing database before filling.

For Utah Medicaid enrollees, testosterone cypionate 200 mg/mL injectable solution is covered at minimal or zero cost-share at most Utah Medicaid pharmacies. The Endocrine Society guideline notes that injectable testosterone formulations produce similar hypogonadism symptom improvements to gel formulations in most patients, though injection site reactions and fluctuating serum levels are real tradeoffs [5].

Discount aggregators such as GoodRx, Blink Health, and Cost Plus Drugs (Mark Cuban's pharmacy) list testosterone gel prices for Utah zip codes. As of early 2026, Cost Plus Drugs listed generic testosterone gel 1.62% (75 g) for approximately $89 per month, though prescriptions must be sent to their mail-order facility rather than a local Utah pharmacy [11].

A 2021 JAMA study found that GoodRx prices for common drugs were lower than insurance cost-sharing amounts in 23% of cases, suggesting that cash-plus-coupon may beat insurance copay for some Utah patients depending on their plan [12].

Can You Get AndroGel Via Telehealth in Utah?

Telehealth prescribing of AndroGel is legal in Utah as of 2026. A Utah-licensed physician, nurse practitioner, or physician assistant, or an out-of-state provider with a valid compact license for Utah, may evaluate a patient via video and prescribe testosterone gel if clinical criteria are met. The Ryan Haight Online Pharmacy Consumer Protection Act requires a prescriber to hold a valid DEA registration to prescribe controlled substances via telemedicine; testosterone is a Schedule III controlled substance [13].

Utah participates in the Interstate Medical Licensure Compact and the Nurse Licensure Compact, which streamlines multistate prescribing. This means a provider licensed in Nevada, Colorado, or another compact state may treat Utah patients via telehealth without obtaining a separate Utah license, provided they hold DEA registration covering Utah.

The temporary DEA telemedicine flexibilities implemented during the COVID-19 public health emergency allowed initial prescribing of Schedule III substances without an in-person visit. Those flexibilities were extended through 2025, and the DEA finalized special registration rules for telemedicine prescribing of controlled substances in late 2024, creating a permanent pathway for providers who complete the special registration process [14].

HealthRX operates as a telehealth provider with DEA-registered clinicians who hold prescribing authority in Utah. Patients receive a digital clinical intake, two at-home lab orders to confirm morning testosterone levels, and a video consultation before any prescription is issued. This process aligns with the Endocrine Society's recommendation that testosterone therapy be initiated only after two separate low morning serum testosterone measurements confirm hypogonadism [5].

AndroGel Dosing and What to Expect Clinically

AndroGel 1.62% is applied once daily to the shoulders and upper arms. The starting dose is 40.5 mg (two pump actuations or one unit-dose packet). Serum testosterone is measured 14 days after initiation; the dose may be adjusted to 20.25 mg or increased to 81 mg based on the measured level. Maximum approved dose is 81 mg per day [1].

Target serum testosterone for replacement therapy is generally 400 to 700 ng/dL based on FDA labeling and Endocrine Society guidance, with the goal of restoring physiologic mid-normal range values [1, 5]. Patients should apply the gel to clean, dry, intact skin and wash hands immediately after application to prevent transfer to others.

The T-Trials, which enrolled 788 men aged 65 years and older at 12 U.S. sites, found that men randomized to testosterone gel therapy achieved mean serum testosterone levels of 500 ng/dL at 12 months compared with 230 ng/dL in placebo-treated men, a between-group difference that correlated with improvements in sexual desire scores on the Psychosexual Daily Questionnaire [2]. The trial used AndroGel specifically as the testosterone formulation, giving it high relevance for Utah prescribers evaluating topical gel therapy.

Transfer to women and children is the primary safety concern with topical testosterone. The FDA added a black box warning to AndroGel labeling after reports of secondary exposure in pediatric patients caused virilization [1]. Patients should allow the gel to dry fully before clothing contact and should not let children or women touch application sites.

Utah-Specific Pharmacy and Provider Considerations

Salt Lake City houses the highest concentration of compounding pharmacies in Utah, with several in the Sugar House, Millcreek, and downtown corridors holding 503A licensure. Provo and Ogden each have two to three 503A facilities as of 2026. Rural Utah patients in areas such as Moab, Cedar City, and St. George increasingly rely on mail-order compounding pharmacies that ship within Utah under valid 503A authority.

Utah's pharmacy board, the Utah Division of Occupational and Professional Licensing (DOPL), maintains a public license verification tool that allows patients to confirm that a compounding pharmacy holds an active license before filling a prescription. Using an unlicensed compounding pharmacy carries regulatory and safety risk, as those facilities are not subject to state or federal oversight inspections [15].

Prior authorization processing time for AndroGel at Utah commercial insurers averages five to seven business days when supporting documentation includes lab results, symptom documentation, and a failure or contraindication note for generic testosterone gel. Submitting incomplete prior authorization requests is the single most common cause of delay, according to Utah pharmacy benefit manager processing data reviewed by the HealthRX medical team.

Safety Monitoring for Testosterone Gel Users in Utah

Patients on testosterone gel require periodic monitoring. The Endocrine Society recommends checking hematocrit three to six months after initiation and then annually, because testosterone stimulates erythropoiesis and can raise hematocrit above 54%, a threshold at which therapy should be interrupted or dose reduced [5]. PSA should be measured at three to six months in men over 40 and annually thereafter per the same guideline.

Bone density measurement (DXA) is appropriate for hypogonadal men with osteoporosis or significant fracture risk, given that the T-Trials demonstrated a 3.5% increase in volumetric bone mineral density of the spine in testosterone-treated men versus 1.0% in placebo after 12 months (P<0.001) [16].

Cardiovascular risk requires careful evaluation. The FDA added a label update in 2015 requiring testosterone products to warn about a possible increased risk of cardiovascular events; subsequent data from the TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement was noninferior to placebo for major adverse cardiovascular events in middle-aged and older men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk [17]. Utah prescribers should review TRAVERSE data with patients who express cardiovascular concerns.